Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05276531
Other study ID # 18.10.2021-E.36477
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date April 1, 2022
Est. completion date September 1, 2022

Study information

Verified date September 2022
Source Bezmialem Vakif University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The invesigators aimed to seperate the patients,which is going to be applied IUI, to two different groups as prospective randomized controlled ;assess the efficacy of the two different way pressurised progesterone by appling intravaginal progesterone to the first group; subcutaneous to the second group.


Description:

Approxymately %10-15 of the couples who are in reproductive age ,have infertility issues. %30-40 male factor ,%40-50 female factor and %20-25 both factors play a role in infertility etiology. Contributory factors of cases are %30-40 male factors, %40-50 female factors and %20-25 mixed type. Ovulation induction and intrauterine insemination(IUI) are the main treatments in infertility.IUI is accepted as the most used treatment procedure according to other assisted reproductive techniques because it has lower costs ,can be easy applied and less invasive.Luteal phase ,which is approximately 14 days,is identified as between the time of ovulation and the beginning of the menstruation period. The production of progesterone in this period,is related to the function of corpus luteum. Progesterone is used as luteal support in patients which are applied ovulation induction with gonadotropin(GND). Gonadotropin is going to be used for controlled ovarian stimulation. The treatment is going to be started on second or third day of the cycle and GND dose is going to be determined according to the patient's age, body mass index, ovary reserve and past stimulation dose answer. Treatment processed gonadotropin dose is going to be arranged according to the follicle's progress and endometrial thickness. Human chorionic gonadotropin(hCG) is going to be added to the treatment when dominant follicle's diameter reached to 17-18mm for occuring of the ovulation. Sperm obtained by density gradient method using fresh sperm 36 hours after hCG, is going to be applied to the female partner with the help of a soft catheter in the dorsalitotomy position under ultrasound guidance. The patient is going to be kept in the supine position after the procedure for 15 minutes. Each patient is going to be given a single insemination and told to resume sexual intercourse for 3 days after the procedure. Intravaginal progesterone once a day to the first group after insemination to the patients divided into two different groups with randomized controlled (LUTINUS® 100 mg vaginal tablet, Ferring GmbH Wittland/Kiel/Germany) , second group subcutaneous progesterone (PROLUTEX® 25 mg Solution for injection, IBSA Group, Lugano, Switzerland) is going to be used once a day. Clinical pregnancy rates are going to be recorded by performing a blood pregnancy test on the 15th day after the procedure. The investigators aimed to separate the patients, who are going to be applied IUI, in to two different groups as prospective randomized controlled; assess the efficacy of the two different way applied progesterone by appling intravaginal progesterone to the first group; subcutaneous to the second group.


Recruitment information / eligibility

Status Completed
Enrollment 146
Est. completion date September 1, 2022
Est. primary completion date June 1, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Absence of follicles larger than 10 mm on basal ultrasound - Endometrial thickness less than 5 mm - Patients with FSH<10 IU/ml, E2<60-80 pg/ml in the blood hormone test performed on the third day of the cycle and patients with antral follicle count above 7 on ultrasound - Total motile sperm count greater than 10 million/ml - 18-40 years old female, 18-50 years old male - Anovulation, patients diagnosed with unexplained mild male factor infertility - Female partners, who's BMI<25 kg/m² - Being voluntarily Exclusion Criteria: - Other infertility reasons - The patients who doesn't meet the criterias - Refusing to attend to the research

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
subcutaneous progesterone
clinical pregnancy rates
vaginal progesterone
clinical pregnancy rates

Locations

Country Name City State
Turkey Bezmialem Vakif University Istanbul

Sponsors (1)

Lead Sponsor Collaborator
Bezmialem Vakif University

Country where clinical trial is conducted

Turkey, 

References & Publications (7)

Erdem A, Erdem M, Atmaca S, Guler I. Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomized study. Fertil Steril. 2009 Jun;91(6):2508-13. doi: 10.1016/j.fertnstert.2008.04.029. Epub 2008 Aug 9. — View Citation

Green KA, Zolton JR, Schermerhorn SM, Lewis TD, Healy MW, Terry N, DeCherney AH, Hill MJ. Progesterone luteal support after ovulation induction and intrauterine insemination: an updated systematic review and meta-analysis. Fertil Steril. 2017 Apr;107(4):924-933.e5. doi: 10.1016/j.fertnstert.2017.01.011. Epub 2017 Feb 24. Review. — View Citation

Keskin M, Aytaç R. Does Luteal Phase Support Effect Pregnancy Rates in Intrauterine Insemination Cycles? A Prospective Randomised Controlled Study in a Tertiary Center. Obstet Gynecol Int. 2020 Aug 5;2020:6234070. doi: 10.1155/2020/6234070. eCollection 2020. — View Citation

Khosravi D, Taheripanah R, Taheripanah A, Tarighat Monfared V, Hosseini-Zijoud SM. Comparison of oral dydrogesterone with vaginal progesteronefor luteal support in IUI cycles: a randomized clinical trial. Iran J Reprod Med. 2015 Jul;13(7):433-8. — View Citation

Maher MA. Luteal phase support may improve pregnancy outcomes during intrauterine insemination cycles. Eur J Obstet Gynecol Reprod Biol. 2011 Jul;157(1):57-62. doi: 10.1016/j.ejogrb.2011.03.022. Epub 2011 Apr 21. — View Citation

Oktem M, Altinkaya SO, Yilmaz SA, Bozkurt N, Erdem M, Erdem A, Gumuslu S. Effect of luteal phase support after ovulation induction and intrauterine insemination. Gynecol Endocrinol. 2014;30(12):909-12. doi: 10.3109/09513590.2014.947567. Epub 2014 Aug 7. — View Citation

Ozcan P, Takmaz T. Identification of predictive factors for the probability of pregnancy following ovulation stimulation-intra-uterine insemination cycles in terms of female and male. J Obstet Gynaecol Res. 2021 Mar;47(3):893-899. doi: 10.1111/jog.14594. Epub 2021 Jan 5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary clinical pregnancy rate after iui betahcg levels blood sampling day 15
Secondary Ongoing pregnancy rate Ongoing pregnancy rates 3 months after iui Months 3
See also
  Status Clinical Trial Phase
Completed NCT03340701 - Pharmacokinetics of Progesterone in Pregnancy Phase 1
Completed NCT04535973 - Hormonal Status and Quality of Life in Female Postmenopausal Patients With Burning Mouth Syndrome
Completed NCT03740568 - Effect of Intervention on Progesterone Levels Before Euploid Embryo Transfer in Pregnancy Outcomes. N/A
Terminated NCT04140968 - Progesterone and Resting Energy Expenditure Phase 4
Completed NCT03677336 - Oral Dydrogesterone (OD) Versus Micronized Vaginal Progesterone (MVP) for Luteal Phase Support (LPS) in IVF/ICSI Phase 4
Not yet recruiting NCT03456570 - The Efficacy of Progestins in Treatment of Functional Ovarian Cyst Early Phase 1
Completed NCT05742503 - Progesterone Containing Contraceptive Methods on Endogenous Progesterone Level
Completed NCT02323347 - Cut-Off Progesterone Values Deleterious for In Vitro Fertilization and Fresh Embryo Transfer N/A
Completed NCT00264407 - Neural Changes in the Aging Auditory System Phase 1
Recruiting NCT04124913 - Oral Dydrogesterone vs. Micronized Vaginal Progesterone for Luteal Phase Support in Frozen-thawed Embryo Transfer Cycles Phase 4
Completed NCT03734770 - Patient's Preferences About Subcutaneous or Vaginal Progesterone Administration for Luteal Phase Support N/A
Completed NCT04253470 - Debate on Progesterone Elevation on the Day of Triggering
Completed NCT04769401 - Effects of E2, P4 and LH Levels on the Day of Transfer and Endometrial Cavity Thickness on Implantation Success in Patients With Frozen-thawed Embryo Transfer Cycle N/A
Recruiting NCT05481684 - The Importance of Embryo Transfer Day Progesterone Value in Natural Cycle Frozen Embryo Transfers and the Evaluation of the Effect of Rescue Therapy on Pregnancy Outcomes in Patients With Low Progesterone Levels N/A